SCHAUMBURG, Illinois — Injectable drug manufacturer Sagent Pharmaceuticals closed its second $30 million Series A extension this week to help launch new products and other activities, the company stated.
Sagent originally raised $53 million in its first round in September 2007 and followed a year later with a $30 million extension. Vivo Ventures has lead each portion of this first-round fund raise.
The company has nine injectables for cardiovascular and anti-bacterial treatments in the market, six of which were launched in 2008. It launched an injectable Cefazolin, an antibiotic to treat infections, in February.
A Deep-dive Into Specialty Pharma
A specialty drug is a class of prescription medications used to treat complex, chronic or rare medical conditions. Although this classification was originally intended to define the treatment of rare, also termed “orphan” diseases, affecting fewer than 200,000 people in the US, more recently, specialty drugs have emerged as the cornerstone of treatment for chronic and complex diseases such as cancer, autoimmune conditions, diabetes, hepatitis C, and HIV/AIDS.
Sagent stated in its most recent release that it expects to have 20 products launched by year’s end.
